1. US Preventive Services Task Force. Owens DK, Davidson KW, et al. Screening for pancreatic cancer: US Preventive Services Task Force reaffirmation recommendation statement. JAMA. 2019; 322:438–444. DOI:
10.1001/jama.2019.10232. PMID:
31386141.
3. Klein AP, Brune KA, Petersen GM, et al. 2004; Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 64:2634–2638. DOI:
10.1158/0008-5472.CAN-03-3823. PMID:
15059921.
4. Goggins M, Overbeek KA, Brand R, et al. 2020; Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut. 69:7–17. DOI:
10.1136/gutjnl-2019-319352. PMID:
31672839. PMCID:
PMC7295005.
6. Tanaka M, Fernández-Del Castillo C, Kamisawa T, et al. 2017; Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 17:738–753. DOI:
10.1016/j.pan.2017.07.007. PMID:
28735806.
7. Kim SH, Hwang HK, Lee WJ, Kang CM. 2021; Biologic behavior of resected BRCA-mutated pancreatic cancer: comparison with sporadic pancreatic cancer and other BRCA-related cancers. Pancreatology. 21:544–549. DOI:
10.1016/j.pan.2021.02.007. PMID:
33612442.
8. Greenhalf W, Lévy P, Gress T, et al. 2020; International consensus guidelines on surveillance for pancreatic cancer in chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and European Pancreatic Club. Pancreatology. 20:910–918. DOI:
10.1016/j.pan.2020.05.011. PMID:
32624419.